Cresco Labs (CRLBF) Projected to Post Quarterly Earnings on Thursday

Key Points

• Cresco Labs is expected to announce its quarterly earnings on August 7th, with analysts predicting earnings of ($0.03) per share and revenue of $162 million.
• The company reported a negative net margin of 11.86% and a negative return on equity of 21.77% for its last earnings report in May.
• The stock price of Cresco Labs increased by 6.8%, closing at $0.64 and currently holds a market capitalization of approximately $314.94 million.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $162.00 million for the quarter.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last released its earnings results on Friday, May 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Cresco Labs had a negative return on equity of 21.77% and a negative net margin of 11.86%. The company had revenue of $165.76 million for the quarter, compared to the consensus estimate of $164.37 million. On average, analysts expect Cresco Labs to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cresco Labs Stock Up 4.5%

OTCMKTS CRLBF traded up $0.03 during trading hours on Friday, hitting $0.62. 1,300,179 shares of the company traded hands, compared to its average volume of 798,477. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.98 and a current ratio of 2.75. The business's 50-day moving average is $0.56 and its 200-day moving average is $0.71. The stock has a market capitalization of $304.43 million, a price-to-earnings ratio of -2.58 and a beta of 1.42. Cresco Labs has a twelve month low of $0.43 and a twelve month high of $2.05.

Analyst Ratings Changes

Separately, Canaccord Genuity Group cut shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy".

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.